Chromium Supplementation in Women with Polycystic Ovary Syndrome: Systematic Review and Meta-Analysis

The document reviewed the impact of chromium picolinate (CrP) supplementation on 351 women with polycystic ovary syndrome (PCOS) across six randomized controlled trials. It found that while CrP significantly reduced insulin resistance, it unexpectedly increased total and free testosterone levels, with no significant changes in other insulin metabolism parameters, hormone levels, or lipid profiles. The study concluded that CrP does not significantly improve insulin metabolism, hormone status, or lipid profiles in PCOS patients and highlighted the need for more uniform and high-quality clinical trials to verify these findings. Safety concerns were noted but not extensively analyzed, with chromium considered relatively safe based on previous studies.